Cara Therapeutics, Inc. (CARA.O)

Cara Therapeutics, Inc. (CARA.O) Trading on MT5 at XM

At XM we offer Cara Therapeutics, Inc. (CARA.O) stocks as cash CFDs. Our cash CFDs stocks are undated transactions that aim to replicate the cash price of the underlying stock, and so they are adjusted for any relevant corporate actions.

Open a Demo Account
Open an Account

Risk warning: FX and CFD trading involves a high risk of loss.

About Cara Therapeutics, Inc. (CARA.O) Trading

Cara Therapeutics, Inc. is an American biotechnology company that develops anti-inflammatory pharmaceutical products for the treatment of acute and chronic pain, and pruritus. The company features a series of product brands developed to exclude the side-effects of traditional pain relief medication. The company stock CARA.O is traded on the Nasdaq Stock Market.

Trading Conditions

Margin requirement 15 %
Spreads as low as 0.13
Symbols CaraTherapeutics
Description CaraTherapeutics
Min. Price Fluctuation 0.01000
Value of Minimum Price Fluctuation USD 0.1
Value of 1 lot 10 Shares
Min/Max Trade Size 1/317
Swap Value in Margin Currency Long -3.2 %
Swap Value in Margin Currency Short -2.8 %
Limit and Stop Levels** 0.04
Total Volume Limit (per client)*** 2998
Weekday 16:40-22:55 (GMT +3)
Monday Open 16:40 (GMT +3)   │   Friday Close 22:55 (GMT +3)
** Min. level for placing pending orders at a current market price.

*** Note that the maximum trading volume for CaraTherapeutics per client is 2998 lots. This limit will be reviewed on a daily basis and updated according to the value of the instrument.

How to Start Trading Cara Therapeutics, Inc. (CARA.O)?

Step 1

Open an XM Real Account

Step 2

Download and login to the MT5 platform

Step 3

Double-click on Cara Therapeutics, Inc. (CARA.O) from the “Market Watch” to open an order for this instrument.

We are using cookies to give you the best experience on our website. Read more or change your cookie settings.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.